Sign up to save your podcasts
Or
Share NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
NEJM at ESMO — Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
View all episodes
By NEJM Group
4.4
120120 ratings
Did you miss the ESMO Congress 2024? Listen here: NEJM Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research that was presented at the 2024 European Society of Medical Oncology annual meeting. Visit NEJM.org to read the latest research.
More shows like NEJM Interviews
View all
JAMA Editors' Summary
136 Listeners
NEJM This Week
318 Listeners
JAMA Clinical Reviews
498 Listeners
JACC This Week
169 Listeners
Clinical Conversations
58 Listeners
Mayo Clinic Talks
296 Listeners
BMJ Best Practice Podcast
20 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
137 Listeners
Core IM | Internal Medicine Podcast
1,149 Listeners
Curbside Consults
91 Listeners
Leadership Conversations
5 Listeners
Annals On Call Podcast
193 Listeners
JAMA Medical News
94 Listeners
The Clinical Problem Solvers
512 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
367 Listeners
Cardionerds: A Cardiology Podcast
428 Listeners
The Curious Clinicians
370 Listeners
NEJM AI Grand Rounds
61 Listeners
Intention to Treat
31 Listeners
Not Otherwise Specified
64 Listeners